Principal Investigators

    Ira Hebold Haraldsen


    Oslo University Hospital

    Contact information of lead PI



    Title of project or programme

    Development of a Novel F18-PET tracer for early diagnosis of Alzheimers Dementia

    Source of funding information


    Total sum awarded (Euro)

    € 731,200

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Research Abstract

    Our primary objective is to develop a F18-GnRH PET-tracer for pre-symptomatic diagnosis of AD.
    Our secondary objectives are:
    Development of a 3rd generation library of compounds to optimize the brain uptake, specific binding and metabolic stability.
    Screen for lead candidates according to selection criteria
    Estimate the binding potential of GnRH tracers in rodent brain sections (Bmax/Kd) to assess the expected signal strength of specific binding of the tracer.
    Estimate the binding potential of GnRH tracer s in human brain sections (Bmax/Kd) (as above).
    Dynamic in vivo PET in rats (correlation to receptor distribution as measured by immunohistochemical staining patterns).
    Dynamic displacement / pre-blockage of tracer uptake by treatment with a non-radioac tive GnRH-affine compound (for quantification/specificity of signal).
    Outsourcing of ADMET-studies (Absorption, distribution, metabolism, excretion, toxicity) for preparation of clinical applications

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: Norway
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF